


REMARKS

Applicants respectfully request the Examiner to enter this Preliminary Amendment. Claims 2-12, and 15-17 have been rewritten to remove multiple dependencies and to more particularly point out the subject matter Applicants consider the invention. A marked-up copy of the claims showing all the changes is submitted herewith. No new matter has been added by these amendments. Support for the amendments is found in the specification as originally filed. With these amendments, the claims pending are 1-19.

Applicants respectfully solicit allowance of the claims as amended and passage of the case to issuance. If in the opinion of the Examiner a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney at (312) 913-0001

Respectfully submitted,



Stephen H. Docter, Registration No. 44,659
One of the Attorneys for Applicant(s)
McDonnell, Boehnen, Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001 (telephone)
(312) 913-0003 (facsimile)

Date: March 13, 2001

Marked-up Version of Claims 2-12 and 15-17

2. (Amended) The use ~~Use~~ according to claim 1: wherein the liver tumor is a tumor primarily confined to the liver.

3. (Amended) The use ~~Use~~ according to claim 2: wherein the tumor primarily confined to the liver is a hepatocellular carcinoma (HCC) or a cholangiocarcinoma.

4. (Amended) The use ~~Use~~ according to claim 1: wherein the tumor is a liver metastasis.

5. (Amended) The use ~~Use~~ according to claim 1 ~~any one of the preceeding claims~~ wherein the intrahepatic administration of MMDX is via the hepatic artery.

6. (Amended) The use ~~Use~~ according to claim 1 ~~any one of the preceeding claims~~ wherein MMDX is administered as an infusion of from about 15 minutes to about 30 minutes every 4 weeks.

7. (Amended) The use ~~Use~~ according to ~~anyone of claims 1- to 6:~~ wherein MMDX is administered as a 5-10 minute bolus every 8 weeks.

8. (Amended) The use ~~Use~~ according to claim 1 ~~any one of the preceeding claims~~ wherein MMDX is administered with an agent which remains selectively in a liver tumor after its injection through the hepatic artery.

9. (Amended) The use ~~Use~~ according to claim 8: wherein the agent is iodized oil.

10. (Amended) The use ~~Use~~ according to claim 1 ~~any one of the preceeding claims~~ wherein MMDX is administered in a dose ranging from about 100 mcg/m² to about 1000 mcg/m².

09796009-061404
F01T90-0606260

11. (Amended) ~~The use~~—Use according to claim 10, wherein MMDX is administered in a dose ranging from about 100 mcg/m² to about 800 mcg/m².

12. (Amended) The use ~~Use~~ according to claim 11, wherein the dose is 200 mcg/m².

15. (Amended) ~~The use~~ Use of a pharmaceutical composition according to claim 13 or 14, for the treatment of a liver tumor.

16. (Amended) ~~The use~~ Use of a pharmaceutical composition which comprises as an active principle MMDX and a pharmaceutically acceptable agent which remains selectively in a liver tumor after its injection through the hepatic artery, for the preparation of a medicament formulated for intrahepatic administration in the treatment of a human liver tumor.

17. (Amended) The use~~Use~~ according to claim 16 wherein the agent is iodized oil.